http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005096349-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ba102ea9c02b6633d64bf09c5b89a4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate | 2003-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2e8c3e3928f923ded0fde1f5520e1ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_253d89425c1b95eddc8d443a3f253f07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a814e53c70471971ac369ef08dfe9a18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_446274a6b166967ac6790273eb5d9750 |
| publicationDate | 2005-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005096349-A1 |
| titleOfInvention | Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning |
| abstract | Many medications, herbal remedies and procedures have side affects that contribute to cognitive dysfunction. Because of these side effects patients may choose to discontinue medication or treatment (such as ECT) which has a detrimental effect on treatment. Currently, there are no medications approved for helping to alleviate these symptoms. The invention describes a novel treatment for individuals who experience various side effects of cognitive dysfunction. The invention additionally describes how these medications may enhance cognitive function in individuals with normal cognitive functioning who might benefit from this type of enhancement. The subject invention further provides materials and methods for the treatment, prevention, or ameliorate medication-induced cognitive dysfunction comprising the administration of medications or compositions comprising at least one selective norepinephrine reuptake inhibitors (SNR1) and/or buproprion. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010044016-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009247528-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005152974-A1 |
| priorityDate | 2003-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.